HomeNewsIndiaOmicron could spread faster but it''s still not certain: WHO

Omicron could spread faster but it''s still not certain: WHO

The comments come among swirling concerns about the new variant that first emerged in southern Africa last month, prompting some countries to shut their borders and rattling stock markets fearful of the long-term impact of a possible new variant of the virus that has already infected at least 267 million people and killed more than 5.2 million.

December 09, 2021 / 08:49 IST
Omicron variant [Representative image]

The World Health Organization says early evidence suggests the omicron variant may be spreading faster than the highly transmissible delta variant but brings with it less severe coronavirus disease – though it’s too early to make firm conclusions.

The comments come among swirling concerns about the new variant that first emerged in southern Africa last month, prompting some countries to shut their borders and rattling stock markets fearful of the long-term impact of a possible new variant of the virus that has already infected at least 267 million people and killed more than 5.2 million.

Dr. Michael Ryan, WHO’s chief of emergencies, told reporters Wednesday that data about the omicron variant so far is pointing to a virus that’s efficiently transmitting and probably more efficiently transmitting than even the delta variant, which is by far the most widespread and deadly version.

Maria Van Kerkhove, the technical lead for COVID-19 at the U.N. health agency, cautioned that it was too early to determine the severity of disease caused by omicron, saying there’s only anecdotal information about that for now.

We certainly have information from South Africa that many of the patients that are identified with omicron have a more mild course of disease, she said. But it does take time for people to go through the full course of their infection.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Meanwhile, WHO officials stuck to their stance that giving booster shots to people who are already vaccinated should be a secondary priority to getting first doses into the arms of people in places that have relatively little vaccination coverage.

Dr. Soumya Swaminathan, the WHO’s chief scientist, said wholesale boosting is not the solution right now. That appeared to be an allusion to policies in some countries, notably in hard-hit Europe and the United States, that encourage broad categories of people to get booster shots, not just groups that are seen as especially vulnerable.

The data from country after country after country is showing that the people who are in the ICUs, the people who are severely ill, and the people who are dying are the unvaccinated, she said.

I think the message is loud and clear that it’s a primary course of vaccination that is going to protect against severe disease and death — that has to be our goal. Boosters, she added, aren’t useful in countries with large vaccine supplies but where up to 50% of people have not gotten vaccinated, whether out of concern for secondary effects or other reasons.

At this point, the benefits that we will get from reaching those people who have not received primary courses of vaccination are going to be higher than giving additional doses to those who have already completed a primary course, Swaminathan said.

The agency had hoped to vaccinate priority populations the elderly, people with weaker immune systems and health care workers – in all countries by the end of this year. But rich countries with big vaccine stockpiles have monopolized most doses. (AP)

PTI
first published: Dec 9, 2021 08:51 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347